- Home
- IDYA vs HAYW Comparison
IDYA vs HAYW Comparison
Compare IDYA & HAYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- HAYW
- Stock Information
- Founded
- IDYA 2015
- HAYW 1925
- Country
- IDYA United States
- HAYW United States
- Employees
- IDYA N/A
- HAYW N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- HAYW Electronic Components
- Sector
- IDYA Health Care
- HAYW Technology
- Exchange
- IDYA Nasdaq
- HAYW Nasdaq
- Market Cap
- IDYA 2.9B
- HAYW 3.3B
- IPO Year
- IDYA 2019
- HAYW 2021
- Fundamental
- Price
- IDYA $34.21
- HAYW $15.55
- Analyst Decision
- IDYA Buy
- HAYW Buy
- Analyst Count
- IDYA 14
- HAYW 4
- Target Price
- IDYA $49.58
- HAYW $18.00
- AVG Volume (30 Days)
- IDYA 992.0K
- HAYW 2.3M
- Earning Date
- IDYA 11-04-2025
- HAYW 10-29-2025
- Dividend Yield
- IDYA N/A
- HAYW N/A
- EPS Growth
- IDYA N/A
- HAYW 44.13
- EPS
- IDYA N/A
- HAYW 0.62
- Revenue
- IDYA $214,834,000.00
- HAYW $1,099,855,000.00
- Revenue This Year
- IDYA $90.17
- HAYW $6.69
- Revenue Next Year
- IDYA $217.29
- HAYW $5.53
- P/E Ratio
- IDYA N/A
- HAYW $25.10
- Revenue Growth
- IDYA 5377.66
- HAYW 9.66
- 52 Week Low
- IDYA $13.45
- HAYW $11.10
- 52 Week High
- IDYA $34.66
- HAYW $17.73
- Technical
- Relative Strength Index (RSI)
- IDYA 68.23
- HAYW 47.56
- Support Level
- IDYA $31.15
- HAYW $14.98
- Resistance Level
- IDYA $34.66
- HAYW $16.41
- Average True Range (ATR)
- IDYA 1.58
- HAYW 0.40
- MACD
- IDYA 0.11
- HAYW -0.12
- Stochastic Oscillator
- IDYA 89.86
- HAYW 41.47
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About HAYW Hayward Holdings Inc.
Hayward Holdings is a leading manufacturer of energy-efficient swimming pool equipment and pool automation systems. The company offers a wide range of pool equipment, including pumps, filters, heaters, LED lights, and sanitization. Headquartered in Charlotte, North Carolina, the company has around 2,000 full-time employees. Hayward generated approximately $1.1 billion in revenue in 2024.